Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Doping control from a global and national perspective.

Albert D Fraser1

  • 1Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada. adfraser@dal.ca

Therapeutic Drug Monitoring
|July 2, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of fluid load on human urine characteristics related to workplace drug testing.

Journal of analytical toxicology·2012
Same author

Brain cyclosporin A levels are determined by ontogenic regulation of mdr1a expression.

Drug metabolism and disposition: the biological fate of chemicals·2005
Same author

Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation.

European journal of clinical pharmacology·2005
Same author

Urinary excretion profiles of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and 11-hydroxy-delta9-THC: cannabinoid metabolites to creatinine ratio study IV.

Forensic science international·2004
Same author

Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2004
Same author

Impact of lowering the screening and confirmation cutoff values for urine drug testing based on dilution indicators.

Therapeutic drug monitoring·2003

This paper traces the history of doping in sports and the establishment of the World Anti-Doping Agency (WADA). It details the World Anti-Doping Code, including the Therapeutic Use Exemptions (TUE) program, and discusses challenges in global anti-doping efforts.

Area of Science:

  • Sports Science
  • Anti-Doping Research
  • Public Health

Background:

  • Athletic performance enhancement with foreign substances has a long history, dating back to the ancient Olympic Games.
  • The International Olympic Committee (IOC) established a Medical Commission in 1967 to combat doping, leading to the introduction of drug tests in 1968.
  • A pivotal World Conference on Doping in Sport in 1999 led to the creation of the World Anti-Doping Agency (WADA).

Observation:

  • WADA was formed in 1999 with equal representation from the Olympic movement and public authorities.
  • A key WADA mandate was to harmonize anti-doping codes globally, resulting in the World Anti-Doping Code and International Standards (IS).
  • International Standards cover laboratories, testing, prohibited substances, and Therapeutic Use Exemptions (TUEs).

Findings:

Related Experiment Videos

  • The World Anti-Doping Code defines a TUE as permission to use prohibited substances for therapeutic reasons.
  • The Canadian Centre for Ethics in Sport Doping Control Review Board's 12-year experience with TUEs is presented.
  • Harmonizing anti-doping efforts requires commitment from sports organizations, athletes, and public authorities.

Implications:

  • Developing a robust global anti-doping program necessitates widespread acceptance of doping as a significant issue.
  • Preserving the integrity of sport requires stakeholders to remain vigilant against doping.
  • These efforts are crucial for the well-being of elite athletes and society at large.